Emicizumab prophylaxis in children with hemophilia A with factor VIII inhibitors in China (HAVEN 5)
Authors:
Open Access
- 2 April 2026
- journal article
- other
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 139 (16) , 2505-2507
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeksResearch and Practice in Thrombosis and Haemostasis, 2023
- BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids TrialThrombosis and Haemostasis, 2023
- Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)Research and Practice in Thrombosis and Haemostasis, 2022
- Low immunogenicity of emicizumab in persons with haemophilia AHaemophilia, 2021
- WFH Guidelines for the Management of Hemophilia, 3rd editionHaemophilia, 2020
- Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation StudyBlood Advances, 2020
- A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitorsBlood, 2019
- A multicentre, open‐label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitorsHaemophilia, 2019
- A first-in-human phase 1 study of ACE910, a novel factor VIII–mimetic bispecific antibody, in healthy subjectsBlood, 2016
- Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia AJournal of Thrombosis and Haemostasis, 2015